Liposomes and micelles in cacner chemotherapy

Drug Delivery System

Volumn 16, Issue 5, 2001, Pages 401-408

  Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

doxil; liposome; micelle; NK 911; passive targeting

Indexed keywords

EID: 0012605563     PISSN: 09135006     EISSN: 18812732     Source Type: Journal    
DOI: 10.2745/dds.16.401     Document Type: Article

References (44)

1. Folkman J, Cotran R : Relation of vascular proliferation to growth. Int Rev Pathol 16 : 207-248, 1976.
2. Matsumura Y, Maeda H : A new concept for macromolecular therapeutics in cancer chemotherapy : Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 : 6387-6392, 1986.
3. Maeda H, Matsumura Y : Tumoritropic and lymphotropic principles of macromolecular Drugs. Critical reviews in therapeutic drug cancer systems 6 : 193-210, 1989.
4. Dvorak HF, Nagy JA, Dvorak JT et al. : Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133 : 95-109, 1988.
5. Dvorak HF : Tumors : wounds that do not heal : similarities between tumor stroma generation and wound healing 315 : 1650-1659, 1986.
6. Matsumura Y, Maruo K, Kimura M et al. : Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn J Cancer Res 82 : 732-741, 1991.
7. Gabizon A, Chemla M, Tzemach D : Liposome Longevity and Stability in Circulation : Effects on the in Vivo Delivery to Tumor and Therapeutic Efficacy of Encapsulated Anthracyclirtes. J Drug Targeting 3 : 391-398, 1996.
8. Sakakibara T, Chen F-A, Kida H : Doxorubicin Encapsulated in Sterically Stabilized Liposomes Is Superior to Free Drug or Drug-containing Conventional Liposomes at Suppressing Growth and Metastases of Human Lung Tumor Xenografts. Cancer Res 56 : 3743-3746, 1996.
9. Unezaki S, Maruyama K, Hosoda J-I : Direct measurement of the extravasation of polyehyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharmaceut 144 : 11-17, 1996.
10. Lasic D : Doxorubicin in sterically stabilized liposomes. Nature 561-562, 1996.
11. Gabison A, Catane R, Uziely R : Prolonged circulation time and enhanced accumulation in malignan exudates of doxorubicine encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54 : 987-992, 1994.
12. Harrington KJ et al. : Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes. Clin Cancer Res 7 : 243-254, 2001.
13. Koukourakis MI, Koukouraki S, Giatramanolaki A : Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer. J Clin Oncol 17 : 3512-3521, 1999.
14. Northfelt DW, Martin FJ, Working P : Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol : Pharmacokinetics. Tumor Localization, and Safety in Patients with AIDS-Related Kaposi's Sarcoma. J Clin Pharmacol 36 : 55-63, 1996.
15. Safra T, Muggia F, Jeffers S, Tsao-wei DD, Groshen S et al.: Pegylated liposomal doxorubicin (doxil) : reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals Oncol 11 : 1029-1033, 2000.
16. Northfeft D, Dezube B, Thorimes J : Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15 : 653-659, 1997.
17. Harrison M, Tomlinson D, Stewart S : Liposomal-entarapped doxorubicin : an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13 : 914-920, 1995.
18. Cheung TW, Remick SC, Azarnia IV : AIDS-related Kaposi's sarcoma : a phase II study of liposomal doxorubicin. Olin Cancer Res 5 : 3432-3437, 1999.
19. Tulpule A, Yung RC, Wernz J, Espina BM, Myers A et al. : Phase II trial of liposomal daunarubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 16 : 3369-3374, 1998.
20. Ellerhorst J, Bedikian A, Ring S : Phase II Trial of doxil for patients with metastatic melanoma refractory to frontile therapy. Oncol Reports 6 : 1097-1099, 1999.
21. Tsiara S, Kapasali E, Christou L : Administration of a modified chmotherapeutic regimen containing vincristine, liposomal doxorubicine and dexamethasone to multiple myelorna patients : preliminary data. Eur J Haematol 65 : 118-122, 2000.
22. Toma S, Tucci A, Villani G, Carteni G, Spadini N et al. : Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas : a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 20 : 485-491, 2000.
23. Judson I, Radford JA, Harris M : Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group, Eur J Cancer 37 : 870-877, 2001.
24. Samantas E, Kalofonos H, Linardou H : Phase II study of pegylated liposomal doxorubicin : Inactive in recurrent small-cell lung cancer. Ann Oncol 11 : 1395-1397, 2000.
25. Ranson M, Carmicheal J, O'Byrne K : Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin : results of a multicenter phase II trial. J Clin Oncol 16 : 811-812, 1998.
26. Shapairo C, Ervin T, Welles L : Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncoi 17 : 1999.
27. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA et al. : Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer. J Clin Oncol 17 : 1425-1434, 1999.
28. Treat J, Greenspan A, Forst D : Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer : phase II study. J Natl Cancer Inst 82 : 1706-1710, 1990.
29. Markeman M, Kennedy A, Webster K : Phase II trial of Liposomal doxorubicin in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78 : 369-372, 2000.
30. Alan NG, Granai CO et al. : Phase II Study of Liposomal Doxorubicin in Platinum-and Paclitaxel-Refractory Epithelial Ovarian Cancer. J Clin Oncol 18 : 3093-3100, 2000.
31. Muggia F : Phase II study of liposomal doxorubicin in refractory ovarian cancer : antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15 : 987-993, 1997.
32. Batist G, Ramakrishnan G, Rao CS : Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophospahmide compared with Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. J Clin Oncol 19 : 1444-1454, 2001.
33. Northfelt DW, Dezube BJ, Thommes JA : Pegylated-Liposomal Doxorubicin Versus Doxorubicin, Bleomycin, and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma : Results of a Randomized Phase III Clinical Trial. J Clin Oncol 16 : 2445-2451, 1998.
34. Stewart S, Jablonowski H, Goebel F : Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma, International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16 : 683-691, 1998.
35. Gill P : Randomized phase III trial of liposomal dauriorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's Sarcoma. J Clin Oncol 14 : 2353-2364, 1996.
36. Gordon AN, Fleagle JT, Guthrie D et al. : Recurrent epithelial ovarian carcinoma : a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 : 3312-3322, 2001.
37. Ryan C, Fleming G, Janisch L : A phase I study of liposomal doxorubicin (DOXIL) with topotecan. Am J Clin Oncol 23 : 297-300, 2000.
38. Burstein HJ, Ramirez MJ, Petros WP : Phase I study of Doxil and vinorelbine in metastatic breast cancer, Ann Oncol 10 : 1113-1116, 1999.
39. Simon R, Freidlin B, Rubinstein L et al. : Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89 : 1138-1147, 1997.
40. Yokoyama M, Inoue S, Kataoka K et al. : Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Makromol Chem Rapid Commun 8 : 431-435, 1987.
41. Yokoyama M, Miyauchi M, Yamada N et al. : Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res 50 : 1693-1700, 1990.
42. Mizumura Y, Matsumura Y, Hamaguchi T et al. : Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 92 : 328-336, 2001.
43. Matsumura Y, Yokoyama M, Kataoka K et al. : Reduction of the side effects of an antitumor agent, KRN 5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 90 : 122-128, 1999.
44. Kataoka K, Togawa A, Harada A et al.: Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolocules 29 : 8556-8557, 1996.